News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
272,263 Results
Type
Article (14394)
Company Profile (281)
Press Release (257588)
Multimedia
Podcasts (49)
Webinars (7)
Section
Business (80089)
Career Advice (159)
Deals (13496)
Drug Delivery (37)
Drug Development (50700)
Employer Resources (32)
FDA (5807)
Job Trends (5346)
News (145836)
Policy (10364)
Tag
Academia (918)
Accelerated approval (2)
Adcomms (12)
Allergies (52)
Alliances (21796)
ALS (68)
Alzheimer's disease (852)
Antibody-drug conjugate (ADC) (108)
Approvals (5831)
Artificial intelligence (132)
Autoimmune disease (19)
Automation (5)
Bankruptcy (108)
Best Places to Work (4766)
BIOSECURE Act (6)
Biosimilars (44)
Biotechnology (232)
Bladder cancer (59)
Brain cancer (20)
Breast cancer (161)
Cancer (1519)
Cardiovascular disease (120)
Career advice (140)
Career pathing (2)
CAR-T (124)
Cell therapy (340)
Cervical cancer (9)
Clinical research (41345)
Collaboration (560)
Compensation (275)
Complete response letters (13)
COVID-19 (1073)
CRISPR (44)
C-suite (172)
Cystic fibrosis (77)
Data (1594)
Denatured (11)
Depression (32)
Diabetes (142)
Diagnostics (1316)
Digital health (3)
Diversity (2)
Diversity, equity & inclusion (9)
Drug discovery (85)
Drug pricing (30)
Drug shortages (3)
Duchenne muscular dystrophy (93)
Earnings (30420)
Editorial (19)
Employer branding (4)
Employer resources (30)
Events (49006)
Executive appointments (476)
FDA (6576)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (510)
Gene editing (102)
Generative AI (10)
Gene therapy (260)
GLP-1 (370)
Government (1096)
Grass and pollen (2)
Guidances (68)
Healthcare (6683)
Huntington's disease (23)
IgA nephropathy (25)
Immunology and inflammation (96)
Indications (20)
Infectious disease (1140)
Inflammatory bowel disease (119)
Inflation Reduction Act (8)
Influenza (20)
Intellectual property (68)
Interviews (18)
IPO (7437)
IRA (12)
Job creations (872)
Job search strategy (133)
Kidney cancer (7)
Labor market (8)
Layoffs (214)
Leadership (3)
Legal (1615)
Liver cancer (34)
Lung cancer (208)
Lymphoma (105)
Machine learning (5)
Management (7)
Manufacturing (148)
MASH (60)
Medical device (2671)
Medtech (2672)
Mergers & acquisitions (6401)
Metabolic disorders (403)
Multiple sclerosis (53)
NASH (13)
Neurodegenerative disease (71)
Neuropsychiatric disorders (25)
Neuroscience (1272)
NextGen: Class of 2025 (2034)
Non-profit (859)
Now hiring (22)
Obesity (197)
Opinion (105)
Ovarian cancer (66)
Pain (45)
Pancreatic cancer (60)
Parkinson's disease (121)
Partnered (8)
Patents (136)
Patient recruitment (84)
Peanut (35)
People (25763)
Pharmaceutical (47)
Pharmacy benefit managers (5)
Phase I (14565)
Phase II (19198)
Phase III (12202)
Pipeline (923)
Policy (51)
Postmarket research (869)
Preclinical (6157)
Press Release (30)
Prostate cancer (63)
Psychedelics (35)
Radiopharmaceuticals (214)
Rare diseases (297)
Real estate (1429)
Recruiting (13)
Regulatory (8773)
Reports (16)
Research institute (941)
Resumes & cover letters (17)
Rett syndrome (4)
RNA editing (5)
RSV (10)
Schizophrenia (63)
Series A (99)
Series B (66)
Service/supplier (1)
Sickle cell disease (41)
Special edition (12)
Spinal muscular atrophy (117)
Sponsored (12)
Startups (1978)
State (1)
Stomach cancer (4)
Supply chain (23)
Tariffs (12)
The Weekly (37)
Vaccines (217)
Venture capitalists (32)
Weight loss (110)
Women's health (15)
Worklife (2)
Date
Last 7 days (562)
Last 30 days (1708)
Last 365 days (19365)
2025 (6963)
2024 (20695)
2023 (22667)
2022 (27278)
2021 (28402)
2020 (23830)
2019 (16442)
2018 (11892)
2017 (13896)
2016 (11957)
2015 (14478)
2014 (10507)
2013 (7569)
2012 (7610)
2011 (7715)
2010 (7504)
Location
Africa (156)
Alabama (43)
Alaska (2)
Arizona (53)
Arkansas (5)
Asia (17490)
Australia (2970)
California (4042)
Canada (1178)
China (374)
Colorado (152)
Connecticut (154)
Delaware (110)
Europe (37735)
Florida (491)
Georgia (121)
Idaho (16)
Illinois (239)
India (10)
Indiana (94)
Iowa (2)
Japan (78)
Kansas (63)
Kentucky (5)
Louisiana (3)
Maine (11)
Maryland (497)
Massachusetts (3214)
Michigan (72)
Minnesota (151)
Mississippi (1)
Missouri (25)
Montana (14)
Nebraska (4)
Nevada (17)
New Hampshire (14)
New Jersey (1029)
New Mexico (12)
New York (1083)
North Carolina (567)
North Dakota (5)
Northern California (1801)
Ohio (115)
Oklahoma (9)
Oregon (21)
Pennsylvania (766)
Puerto Rico (6)
Rhode Island (19)
South America (217)
South Carolina (5)
Southern California (1553)
Tennessee (25)
Texas (469)
United States (13843)
Utah (56)
Virginia (83)
Washington D.C. (31)
Washington State (365)
Wisconsin (16)
272,263 Results for "prevail therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Scribe Therapeutics to Highlight In Vivo CRISPR-based Genome Editing Data for Duchenne Muscular Dystrophy at ASGCT 2025, in Addition to Joint Presentation with Prevail Therapeutics, a Part of Lilly’s Gene Therapy Division
May 5, 2025
·
3 min read
Press Releases
Scribe Achieves Milestone for In Vivo Program in Collaboration with Prevail Therapeutics, a part of Lilly’s Gene Therapy Division, and Announces ASGCT Joint Presentation on Self-Inactivating AAV Technology for Neurological and Neuromuscular Disorders
April 29, 2025
·
3 min read
Bio NC
Precision BioSciences Announces Return of Programs and Conclusion of Collaboration with Prevail Therapeutics
Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company, today announced the anticipated return of three programs from Prevail Therapeutics Inc., a wholly owned subsidiary of Eli Lilly and Company.
April 16, 2024
·
11 min read
Press Releases
Hemogenyx Pharmaceuticals PLC Announces Strategic Investment from Prevail Partners, LLC
October 2, 2024
·
6 min read
Business
Sangamo Therapeutics Announces Research Evaluation and Option Agreement With Prevail, a Wholly Owned Subsidiary of Lilly, for Novel Engineered Capsids
Sangamo Therapeutics, Inc. today announced it has signed an evaluation and option agreement with Prevail Therapeutics through which Prevail has been granted rights to evaluate certain proprietary adeno-associated virus (AAV) capsids developed by Sangamo and may exercise certain options to license these capsids for multiple undisclosed neurological targets.
July 17, 2023
·
4 min read
Drug Development
NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease
NewAmsterdam Pharma Company N.V. announced that it has met the enrollment target of 9,000 patients for the pivotal Phase 3 PREVAIL cardiovascular outcomes trial evaluating obicetrapib in adult patients with a history of atherosclerotic cardiovascular disease, whose LDL-C is not adequately controlled, despite being on maximally tolerated lipid-lowering therapy.
April 9, 2024
·
9 min read
BriaCell Announces $4 Million Strategic Investment and Clinical Alliance with Prevail Partners, LLC and Prevail InfoWorks, Inc.
BriaCell Therapeutics Corp. announces that the Company has signed a Master Service and Technology Agreement agreement with Prevail InfoWorks, Inc., a Philadelphia, PA based Contract Research Organization, to provide clinical services and technologies for BriaCell’s upcoming pivotal study in advanced metastatic breast cancer.
May 15, 2023
·
5 min read
BriaCell Closes $4 Million Strategic Investment by Prevail Partners, LLC at US$8.63 per Share
BriaCell Therapeutics Corp. is pleased to announce that the Company has completed the previously-announced strategic investment by Prevail Partners, LLC in the Company, in accordance with a stock purchase agreement entered into between the Company and Prevail Partners on May 12, 2023.
May 19, 2023
·
4 min read
Hemogenyx Pharmaceuticals PLC Announces Strategic Investment from Prevail Partners, LLC
Hemogenyx Pharmaceuticals plc, the biopharmaceutical group developing new therapies and treatments for blood diseases, announces that Prevail Partners, LLC, an investment fund, has agreed to invest in the Company through a subscription for 11,066,667 ordinary shares at a price of US$0.075 per share for the total sum of $830,000.
September 18, 2023
·
7 min read
Business
Scribe Announces Collaboration with Prevail, a Wholly Owned Subsidiary of Lilly, to Accelerate In Vivo CRISPR-based Genetic Medicines for Neurological and Neuromuscular Diseases
Scribe Therapeutics Inc. today announced a strategic collaboration with Prevail Therapeutics, a wholly owned subsidiary of Eli Lilly and Company, granting Prevail exclusive rights to Scribe’s CRISPR X-Editing (XE) technologies for the development of in vivo therapies directed to specified targets known to cause serious neurological and neuromuscular diseases.
May 16, 2023
·
2 min read
1 of 27,227
Next
